Glembatumumab vedotin
Glembatumumab vedotin Uses, Dosage, Side Effects, Food Interaction and all others data.
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
| Trade Name | Glembatumumab vedotin |
| Generic | Glembatumumab vedotin |
| Glembatumumab vedotin Other Names | Glembatumumab vedotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in melanoma.
How Glembatumumab vedotin works
CR011 is a fully-human monoclonal antibody which utilizes antibody-drug conjugation (ADC) technology licensed from Seattle Genetics. The ADC technology links vcMMAE, a potent chemotherapeutic, to the CR011 antibody resulting in the antibody-drug conjugate CR011-vcMMAE. CR011-vcMMAE targets GPNMB, a protein located specifically on the surface of melanoma cells. After CR011-vcMMAE binds to GPNMB, it is transported inside the cancer cell where the chemotherapy payload, Auristatin E, is cleaved from the antibody and activated.
Innovators Monograph
You find simplified version here Glembatumumab vedotin
